The Food and Drug Administration had recently approved a new drug for the treatment of atopic dermatitis (eczema), which can ...

近日，礼来的湿疹药物Ebglyss在美国获得了上市批准，此前已于2023年获得欧盟批准，并于今年1月份和6月份分别在日本和加拿大获批。该药物可为无法通过外用药物很好控制的中度至重度湿疹提供一种新的一线生物治疗方法。

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

礼来（Eli Lilly and ...

印第安纳波利斯 - Eli Lilly and Company (NYSE: LLY) 宣布美国食品药品监督管理局(FDA)批准其新型生物制剂EBGLYSS™ ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older ...

The Food and Drug Administration (FDA) has approved Ebglyss™ (lebrikizumab-lbkz) for the treatment of adult and pediatric ...

Eli Lilly and Company has announced FDA approval of EBGLYSS (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis ...

Eli Lilly and Co. ($LLY) announced that the U.S. Food and Drug Administration (FDA) had approved its atopic dermatitis ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab ...

Three years after establishing an immunology unit, Eli Lilly has gained its third FDA approval in the specialty area as the U ...